baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC TUR.WAR.OP.END. 1AE/ DE000HD1FNK6 /

1/24/2025 1:45:36 PM	Chg.+0.880	Bid3:32:00 PM	Ask3:32:00 PM	Underlying	Strike price	Expiration date	Option type
31.290EUR	+2.89%	31.010 Bid Size: 3,000	31.090 Ask Size: 3,000	Argen X NV	314.6296 -	12/31/2078	Call

GlobeNewswire 8/28/2024 argenx to Present at Upcoming Investor Conferences

GlobeNewswire 8/26/2024 MDA Kicks Off Muscular Dystrophy Awareness Month in September with ‘30 Days of Strength’ Campaign wi...

GlobeNewswire 8/12/2024 Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

GlobeNewswire 7/25/2024 argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

GlobeNewswire 7/18/2024 argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 202...

GlobeNewswire 7/16/2024 argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Ge...

GlobeNewswire 7/8/2024 Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

GlobeNewswire 6/25/2024 argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...

GlobeNewswire 6/21/2024 argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropat...

GlobeNewswire 6/17/2024 argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcomi...

GlobeNewswire 6/13/2024 Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

GlobeNewswire 6/4/2024 argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire 5/9/2024 argenx Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 5/7/2024 argenx announces results of Annual General Meeting of Shareholders

GlobeNewswire 5/7/2024 argenx to Present at BofA Securities 2024 Health Care Conference

GlobeNewswire 5/2/2024 argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

GlobeNewswire 4/16/2024 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...

GlobeNewswire 3/27/2024 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

GlobeNewswire 3/26/2024 argenx Announces Annual General Meeting of Shareholders on May 7, 2024

GlobeNewswire 3/26/2024 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...

GlobeNewswire 3/7/2024 argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...

GlobeNewswire 2/29/2024 argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

GlobeNewswire 2/26/2024 argenx to Present at Upcoming Investor Conferences

GlobeNewswire 2/22/2024 argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29,...

GlobeNewswire 2/20/2024 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review f...

UC TUR.WAR.OP.END. 1AE/ DE000HD1FNK6 /

If you wish to receive reply to your feedback, please provide your email address.